TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $799.54M |
| Gross Profit (TTM) | $658.60M |
| EBITDA | $136.45M |
| Operating Margin | 9.02% |
| Return on Equity | 100.30% |
| Return on Assets | 7.28% |
| Revenue/Share (TTM) | $5.61 |
| Book Value | $4.26 |
| Price-to-Book | 14.68 |
| Price-to-Sales (TTM) | 11.45 |
| EV/Revenue | 11.35 |
| EV/EBITDA | 65.07 |
| Quarterly Earnings Growth (YoY) | -70.60% |
| Quarterly Revenue Growth (YoY) | 70.30% |
| Shares Outstanding | $153.08M |
| Float | $135.24M |
| % Insiders | 7.47% |
| % Institutions | 74.60% |
Volatility is currently expanding
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnin.
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). For the analysis, individual patient data from the Phase 3 ULTIMATE I/II pivotal trials for BRIUMVI were reweighted to match pub.
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders.
TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.
Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TGTX and any ticker you trade — then tracks every position and per-strategy win rate.
